Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073431 · ClinicalTrials.gov registry record
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
A clinical trial of Stage IV Lung Cancer AJCC v8 and Stage IV Pancreatic Cancer AJCC v8, sponsored by University of Rochester.
- Recruiting
- Registry status
- 800
- Enrollment target
- 20
- Study locations
NCT06073431 is a study of Stage IV Lung Cancer AJCC v8 and Stage IV Pancreatic Cancer AJCC v8 that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 800 participants, above the 88-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (809% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT06073431, a study of Stage IV Lung Cancer AJCC v8 and Stage IV Pancreatic Cancer AJCC v8, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is stage IV. Patients with these cancer types are at risk for developing cancer cachexia (CC), which is defined as weight loss, muscle loss, and fat loss due to cancer. CC has been associated with reduced physical performance, impaired quality of life, and poorer survival. Many studies that have evaluated treatments for cancer-related weight and muscle loss have aimed to treat all patients with weight loss exactly the same and, unfortunately, have not been successful. Like different cancer types, weight and muscle loss related to cancer may have different causes in different individuals and the best treatment strategy for this condition may not be a one-size-fits-all approach. Information gathered from this study may help researchers develop new diagnostic criteria for CC and design better treatments and clinical trials for cancer-related weight and muscle loss in the future to improve the quality of life in patients with advanced colorectal, lung, or pancreatic cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- OTHER Medical Device Usage and Evaluation
- OTHER Electronic Health Record Review
- OTHER Physical Performance Testing
Study Locations (20)
Colorado
- Rocky Mountain Cancer Centers-Aurora - Aurora
- Boulder Community Foothills Hospital - Boulder
- Rocky Mountain Cancer Centers-Boulder - Boulder
- Rocky Mountain Cancer Centers - Centennial - Centennial
- The Women's Imaging Center - Denver
- Colorado Blood Cancer Institute - Denver
- Rocky Mountain Cancer Centers-Midtown - Denver
- Rocky Mountain Cancer Centers-Rose - Denver
- Rocky Mountain Cancer Centers - Swedish - Englewood
- The Melanoma and Skin Cancer Institute - Englewood
- Rocky Mountain Cancer Centers-Lakewood - Lakewood
- Rocky Mountain Cancer Centers-Littleton - Littleton
- Rocky Mountain Cancer Centers-Sky Ridge - Lone Tree
- Rocky Mountain Cancer Centers-Thornton - Thornton
Delaware
- Beebe South Coastal Health Campus - Millville
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Christiana Care Health System-Christiana Hospital - Newark
- Beebe Health Campus - Rehoboth Beach
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2028-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06073431
The ClinicalTrials.gov registry entry for NCT06073431 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (809% higher). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06073431 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Delaware, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06073431 about?
NCT06073431 is a clinical study titled "LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia". This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is stage IV. Patients with these cancer types are at risk for de...
What is the current status of trial NCT06073431?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2023-12-04. Estimated completion is 2028-09-30.
What conditions does trial NCT06073431 study?
This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma.
What interventions are being tested in trial NCT06073431?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Medical Device Usage and Evaluation (OTHER), Electronic Health Record Review (OTHER), Physical Performance Testing (OTHER).
Who is sponsoring clinical trial NCT06073431?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073431 being conducted?
This trial has 20 study locations across Arkansas, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Lung Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RECRUITING · Phase 2
-
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
RECRUITING · Phase 1
-
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
RECRUITING · NA
Explore more on PlainTrial
Stage IV Lung Cancer AJCC v8
All registered trials for this condition
Stage IV Pancreatic Cancer AJCC v8
All registered trials for this condition
Arkansas
All trials with a study site in Arkansas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.